Raptiva Safety Questions, Raptiva Answers
More Here>>Side Effects - FDA Reports 2006-2008
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y ZWelcome! Patientsville.com provides information about Raptiva side effects. Check out Health Surveys and Health Polls. If you have questions about Raptiva, you can post them to our Doctors or Ask Patient Community about Raptiva.
>> Announcements
Check out our Hospital and Home Care Quality Reports.
Help Community - Post Your Side Effect
Ask Our Doctors about Raptiva
Raptiva Safety Reports
Total Raptiva reports: 425.Raptiva FDA safety alerts: 2005 .
Reported deaths: 32 Reported hospitalizations: 223.
Take Raptiva Side Effects Survey or Share Your Raptiva Story.
Reported Raptiva Side Effects: psoriasis, condition aggravated, pyrexia, headache, fatigue, nausea, blood glucose increased, influenza like illness, arthralgia, arthritis bacterial, oedema peripheral.
More About Raptiva.
Showing 1-50 of 425 Next >
Raptiva Side Effects Report #5259967-4Physician from UNITED STATES reported RAPTIVA problem on Feb 22, 2007. Female patient, 50 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: mycosis fungoides, skin lesion. RAPTIVA dosage: 125 MG/ML, 1/WEEK, SUBCUTANEOUS. Patient recovered.
Raptiva Side Effects Report #5261693-2
RAPTIVA problem was reported by a Physician from UNITED STATES on Feb 22, 2007. Male patient, 60 years of age, weighting 186.1 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: anaemia, dehydration, sinus disorder, syncope. RAPTIVA dosage: 120 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CYCLOSPORINE, OXSORALEN, LIPITOR, NIASPAN ER, ZYRTEC, ZOLOFT. Patient recovered.
Raptiva Side Effects Report #5264433-6
Consumer or non-health professional from UNITED STATES reported RAPTIVA problem on Feb 27, 2007. Female patient, 53 years of age, weighting 239.0 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: dyspnoea, electrocardiogram abnormal, immune system disorder, urticaria. RAPTIVA dosage: 0.8 ML, 1/WEEK, SUBCUTANEOUS. Patient recovered.
Raptiva Side Effects Report #5266642-9
RAPTIVA problem was reported by a Health Professional from ITALY on Feb 22, 2007. Male patient, 59 years of age, was diagnosed with psoriasis, diabetes mellitus and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: cerebral ischaemia, hemianopia, hepatic steatosis, splenomegaly. RAPTIVA dosage: 0.4 MG/KG, 1/WEEK,. During the same period patient was treated with GLIBOMET. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5270137-6
Physician from UNITED STATES reported RAPTIVA problem on Mar 02, 2007. Male patient, 63 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: basal cell carcinoma, condition aggravated, cyst, diverticulitis. RAPTIVA dosage: unknown. During the same period patient was treated with FLAGYL, PREMARIL, FLOMAX, HYDROCHLOROTHIAZIDE. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5270145-5
RAPTIVA problem was reported by a Pharmacist from UNITED STATES on Mar 10, 2007. Male patient, 79 years of age, weighting 167.6 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: hypoaesthesia, muscular weakness. RAPTIVA dosage: unknown. Patient was hospitalized and became disabled. Patient recovered.
Raptiva Side Effects Report #5270596-9
Physician from UNITED STATES reported RAPTIVA problem on Mar 10, 2007. Female patient, 50 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: mycosis fungoides. RAPTIVA dosage: 125 MG/ML, 1/WEEK, SUBCUTANEOUS. Patient recovered.
Raptiva Side Effects Report #5270597-0
RAPTIVA problem was reported by a Health Professional from UNITED STATES on Mar 10, 2007. Female patient, 67 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: monocyte percentage increased, neutrophil count decreased. RAPTIVA dosage: 0.6 ML, 1/WEEK, SUBCUTANEOUS. Patient recovered.
Raptiva Side Effects Report #5271740-X
Consumer or non-health professional from UNITED STATES reported RAPTIVA problem on Mar 05, 2007. Female patient, 58 years of age, weighting 153.9 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: colitis ulcerative. RAPTIVA dosage: 0.7 ML, 1/WEEK, SUBCUTANEOUS. Patient recovered.
Raptiva Side Effects Report #5273313-1
RAPTIVA problem was reported by a Pharmacist from GERMANY on Mar 07, 2007. Female patient, 46 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: cerebellar infarction, dysarthria, dysphagia, visual disturbance. RAPTIVA dosage: 0.8 ML, 1/WEEK, SUBCUTANEOUS. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5273318-0
Consumer or non-health professional from GERMANY reported RAPTIVA problem on Mar 06, 2007. Male patient, 68 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: cerebral haemorrhage, cerebrovascular accident. RAPTIVA dosage: 1 ML, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with ASPIRIN. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5273319-2
RAPTIVA problem was reported by a Health Professional from UNITED KINGDOM on Mar 08, 2007. Male patient, 47 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: antinuclear antibody increased. RAPTIVA dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CYCLOSPORINE. Patient recovered.
Raptiva Side Effects Report #5273643-3
Health Professional from UNITED STATES reported RAPTIVA problem on Mar 21, 2007. Male patient, weighting 150.0 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: tinea infection. RAPTIVA dosage: 0.8 ML EVERY WEEK SQ. During the same period patient was treated with KEFLEX. Patient recovered.
Raptiva Side Effects Report #5274738-0
RAPTIVA problem was reported by a Health Professional from UNITED STATES on Mar 12, 2007. Male patient, 72 years of age, weighting 287.9 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: arterial occlusive disease, cardiac failure congestive, condition aggravated, epistaxis, psoriasis. RAPTIVA dosage: 1.7 ML, SUBCUTANEOUS. During the same period patient was treated with INSULIN, GLUCOTROL, ZOCOR, PRILOSEC, ASPIRIN, LASIX, PROFENTE DM, DIOVAN. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5274739-2
Consumer or non-health professional from UNITED STATES reported RAPTIVA problem on Mar 13, 2007. Female patient, 76 years of age, weighting 140.0 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: diverticulitis. RAPTIVA dosage: 0.6 ML, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CENTRUM SILVER, ASPIRIN. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5278379-0
RAPTIVA problem was reported by a Consumer or non-health professional from UNITED STATES on Mar 09, 2007. Female patient, 38 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: blood pressure increased, chest discomfort, chest pain, fluid retention, weight increased. RAPTIVA dosage: unknown. Patient recovered.
Raptiva Side Effects Report #5278514-4
Physician from UNITED STATES reported RAPTIVA problem on Mar 14, 2007. Male patient, 47 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: antiphospholipid syndrome, deep vein thrombosis. RAPTIVA dosage: 1 ML, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with WATER. Patient recovered.
Raptiva Side Effects Report #5278516-8
RAPTIVA problem was reported by a Physician from UNITED STATES on Mar 13, 2007. Female patient, 22 years of age, was diagnosed with dermatitis atopic and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: facial palsy, infection, tongue blistering. RAPTIVA dosage: unknown. During the same period patient was treated with ALBUTEROL INHALER, FLOVENT, CLARITIN, BIRTH CONTROL S. Patient recovered.
Raptiva Side Effects Report #5279681-9
Consumer or non-health professional from UNITED STATES reported RAPTIVA problem on Mar 12, 2007. Male patient, 43 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: chronic inflammatory demyelinating polyradiculoneuropathy, injection site anaesthesia. RAPTIVA dosage: 125 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with HUMALOG. Patient recovered.
Raptiva Side Effects Report #5281237-9
RAPTIVA problem was reported by a Physician from FRANCE on Mar 09, 2007. Female patient, 54 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: arthralgia, autoimmune disorder, cholelithiasis, condition aggravated, cytolytic hepatitis, dyspnoea exertional, fatigue, hepatic steatosis. RAPTIVA dosage: 0.8ML, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with PREDNISONE, CELLCEPT, IMURAN. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5283275-9
Physician from FRANCE reported RAPTIVA problem on Mar 13, 2007. Male patient, 49 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: myocardial infarction. RAPTIVA dosage: unknown. Patient died.
Raptiva Side Effects Report #5284012-4
RAPTIVA problem was reported by a Physician from UNITED STATES on Mar 15, 2007. Female patient, 45 years of age, weighting 310.0 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: abasia, guillain-barre syndrome, nasopharyngitis. RAPTIVA dosage: 1.4 ML, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with LEVAQUIN, AMARYL, MAXZIDE, ASPIRIN. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5285322-7
Physician from SWITZERLAND reported RAPTIVA problem on Mar 15, 2007. Female patient, 49 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: polyarteritis nodosa. RAPTIVA dosage: unknown. Patient recovered.
Raptiva Side Effects Report #5286893-7
RAPTIVA problem was reported by a Consumer or non-health professional from UNITED STATES on Mar 20, 2007. Male patient, 36 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: haemochromatosis, hepatosplenomegaly, liver function test abnormal. RAPTIVA dosage: unknown. Patient recovered.
Raptiva Side Effects Report #5286894-9
Physician from UNITED STATES reported RAPTIVA problem on Mar 20, 2007. Male patient, 45 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: kaposi's sarcoma. RAPTIVA dosage: unknown. Patient recovered.
Raptiva Side Effects Report #5287070-6
RAPTIVA problem was reported by a Consumer or non-health professional from UNITED STATES on Mar 21, 2007. Male patient, 68 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: transient ischaemic attack. RAPTIVA dosage: 1 ML, 1/WEEK, SUBCUTANEOUS. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5287080-9
Health Professional from UNITED STATES reported RAPTIVA problem on Mar 21, 2007. Male patient, 58 years of age, weighting 175.9 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: bladder cancer. RAPTIVA dosage: 80 MG, 1/WEEK, SUBCUTANEOUS. Patient recovered.
Raptiva Side Effects Report #5289667-6
RAPTIVA problem was reported by a Physician from UNITED STATES on Apr 02, 2007. Male patient, 55 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: cardiac failure congestive, condition aggravated, pharyngolaryngeal pain, psoriasis, renal impairment. RAPTIVA dosage: 1 MG/KG, 1/WEEK. Patient recovered.
Raptiva Side Effects Report #5290170-8
Consumer or non-health professional from UNITED STATES reported RAPTIVA problem on Mar 22, 2007. Male patient, 69 years of age, weighting 289.9 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: blood glucose increased, vomiting. RAPTIVA dosage: unknown. During the same period patient was treated with DILTIAZEM, SIMVASTATIN. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5290257-X
RAPTIVA problem was reported by a Physician from UNITED STATES on Mar 21, 2007. Male patient, 58 years of age, weighting 235.0 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: pancreatitis. RAPTIVA dosage: 1.1 ML, 1/WEEK. During the same period patient was treated with TRICOR, LIPITOR, METFORMIN, COZAAR. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5290258-1
Consumer or non-health professional from UNITED STATES reported RAPTIVA problem on Mar 23, 2007. Male patient, 62 years of age, weighting 261.0 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: nephrolithiasis. RAPTIVA dosage: 1.2 ML, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CITRATE, METFORMIN, GLIPIZIDE, AVANDIA, ZOCOR, GEMFIBROZIL, OMEPRAZOLE, TERAZOSIN. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5290927-3
RAPTIVA problem was reported by a Health Professional from UNITED STATES on Apr 05, 2007. Female patient, weighting 170.0 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: condition aggravated, erythema, eye swelling, feeling hot, inflammation, local swelling, psoriasis, rash, swelling face. RAPTIVA dosage: 0.6 ML EVERY WEEK SQ. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5291038-3
Consumer or non-health professional from SWITZERLAND reported RAPTIVA problem on Apr 07, 2007. Female patient was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: palpitations. RAPTIVA dosage: unknown. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5291077-2
RAPTIVA problem was reported by a Health Professional from SWITZERLAND on Mar 23, 2007. Male patient, 58 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: myocardial infarction. RAPTIVA dosage: unknown. Patient died on 02/10/2007.
Raptiva Side Effects Report #5291937-2
Physician from SWITZERLAND reported RAPTIVA problem on Apr 07, 2007. Female patient was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: lupus-like syndrome. RAPTIVA dosage: unknown. Patient recovered.
Raptiva Side Effects Report #5291946-3
RAPTIVA problem was reported by a Health Professional from SWITZERLAND on Apr 07, 2007. Female patient was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: jaundice, pyrexia. RAPTIVA dosage: 1 MG/KG, 1/WEEK. During the same period patient was treated with PARACETAMOL. Patient recovered.
Raptiva Side Effects Report #5292301-2
Health Professional from SWITZERLAND reported RAPTIVA problem on Apr 03, 2007. Male patient, 55 years of age, was diagnosed with parapsoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: pityriasis rosea. RAPTIVA dosage: 1000 MG, 1/WEEK. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5293658-9
RAPTIVA problem was reported by a Physician from SWITZERLAND on Apr 02, 2007. Female patient was diagnosed with psoriasis, hypertension and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: acute pulmonary oedema, platelet count increased, white blood cell count increased. RAPTIVA dosage: unknown. During the same period patient was treated with ANTIHYPERTENSIVE, HYDROCORTISONE, DILTIAZEM, HYTACAND, MOXONIDINE, RELVENE, PANTOPRAZOLE, PARACETAMOL. Patient was hospitalized. Patient died on 02/14/2007.
Raptiva Side Effects Report #5293738-8
Consumer or non-health professional from UNITED STATES reported RAPTIVA problem on Mar 30, 2007. Male patient was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: epistaxis. RAPTIVA dosage: unknown. During the same period patient was treated with COUMADIN. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5294697-4
RAPTIVA problem was reported by a Pharmacist from UNITED STATES on Apr 09, 2007. Female patient, 54 years of age, weighting 160.0 lb, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: nausea. RAPTIVA dosage: 72MG SC QWEEK. Patient recovered.
Raptiva Side Effects Report #5295531-9
Physician from SWITZERLAND reported RAPTIVA problem on Mar 19, 2007. Female patient, 58 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: erythema multiforme, genital ulceration. RAPTIVA dosage: unknown. During the same period patient was treated with OLFEN. Patient recovered.
Raptiva Side Effects Report #5295532-0
RAPTIVA problem was reported by a Physician from FRANCE on Mar 21, 2007. Female patient, 44 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: acute pulmonary oedema, blood pressure abnormal, blood pressure increased, cardiac disorder, cyanosis, heart rate increased, insomnia, platelet count increased, white blood cell count increased. RAPTIVA dosage: unknown. During the same period patient was treated with ANTIHYPERTENSIVE, HYDROCORTISONE, DILTIAZEM, HYTACAND, MOXONIDINE, RELVENE, PANTOPRAZOLE, ACETAMINOPHEN. Patient was hospitalized. Patient died on 02/14/2007.
Raptiva Side Effects Report #5296005-1
Physician from SPAIN reported RAPTIVA problem on Mar 22, 2007. Male patient, 59 years of age, was diagnosed with erythrodermic psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: corneal disorder, corneal transplant. RAPTIVA dosage: 1.14 MG/KG, 1/WEEK, SUBCUTANEOUS. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5296016-6
RAPTIVA problem was reported by a Physician from AUSTRALIA on Mar 22, 2007. Female patient, 51 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: acute myocardial infarction, pneumonia. RAPTIVA dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with METHOTREXATE, PREDNISOLONE. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5296021-X
Physician from AUSTRALIA reported RAPTIVA problem on Mar 30, 2007. Male patient, 35 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: ankylosing spondylitis, arthropathy. RAPTIVA dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. Patient recovered.
Raptiva Side Effects Report #5296029-4
RAPTIVA problem was reported by a Health Professional from SPAIN on Apr 02, 2007. Male patient, 34 years of age, was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: rosacea. RAPTIVA dosage: unknown. Patient recovered.
Raptiva Side Effects Report #5296527-3
Physician from SWITZERLAND reported RAPTIVA problem on Apr 05, 2007. Male patient was diagnosed with psoriasis, hypertension and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: erythrodermic psoriasis, pemphigoid. RAPTIVA dosage: unknown. During the same period patient was treated with TILDIEM. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5296819-8
RAPTIVA problem was reported by a Physician from SWITZERLAND on Apr 05, 2007. Female patient was diagnosed with psoriasis, arthritis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: inguinal mass, metastases to lung, metastatic neoplasm. RAPTIVA dosage: 1 MG/KG, 1/WEEK. During the same period patient was treated with DEXAMETHASONE, PERINDOPRIL ERBUMINE, PANTOPRAZOLE, FOSAMAX. Patient recovered.
Raptiva Side Effects Report #5297486-X
Consumer or non-health professional from UNITED STATES reported RAPTIVA problem on Apr 09, 2007. Female patient, 80 years of age, was diagnosed with psoriasis and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: guillain-barre syndrome. RAPTIVA dosage: 0.5 ML, 1/WEEK. During the same period patient was treated with LIPITOR, GLUCOTROL. Patient was hospitalized. Patient recovered.
Raptiva Side Effects Report #5297520-7
RAPTIVA problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 05, 2007. Male patient, weighting 176.0 lb, was diagnosed with psoriasis, bronchitis chronic, hypertension, blood cholesterol increased and was treated with RAPTIVA. After drug was administered, patient experienced the following problems/side effects: bladder cancer. RAPTIVA dosage: 80 MG, 1/WEEK. During the same period patient was treated with CYCLOSPORINE, SORIATANE, ADVAIR DISKUS, ALBUTEROL, LISINOPRIL, LIPITOR, CENTRUM SILVER VITAMIN. Patient recovered.
Showing 1-50 of 425 Next >
Drug Information: Efalizumab Injection
URL of this page: http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a604010.html
e fa li zoo' mabWhy is this medication prescribed?
Efalizumab is used to treat chronic (long-lasting) plaque psoriasis (a skin disease in which red scaly patches form on some areas of the body) in patients who cannot be treated with medications that are applied to the skin. Efalizumab is in a class of medications called immunosuppressants. It works by stopping the action of cells in the body that cause the symptoms of psoriasis.
How should this medicine be used?
Efalizumab comes as a powder to mix with sterile water and inject subcutaneously (under the skin). It is usually injected once a week. You should inject efalizumab on the same day every week. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use efalizumab exactly as directed. Do not use more or less of it or use it more often or for a longer period of time than prescribed by your doctor.
Your doctor will probably start you on a low dose of efalizumab and increase your dose after 1 week.
Efalizumab controls chronic plaque psoriasis but does not cure it. It may take several weeks before you feel the full benefit of efalizumab. Do not stop taking efalizumab without talking to your doctor.
You can inject efalizumab yourself or have a friend or relative give the injections. Your doctor will train the person who will be injecting the medication, and will test him to be sure he can give the injections correctly. Be sure that you and the person who will be giving the injections read the manufacturer's information for the patient that comes with efalizumab before you use it for the first time at home.
If you are injecting efalizumab yourself, you can inject it anywhere on your thighs or stomach. If someone else will be giving you your injections, he or she can also inject the medication anywhere on the back of your upper arms or buttocks. To reduce the chances of soreness or redness, choose a different area for each injection. If your doctor has told you to use two injections for each dose, choose two spots that are at least 1 inch apart. Do not inject efalizumab near a vein that you can see through the surface of the skin. Try to inject efalizumab in skin that is free of symptoms of psoriasis.
Never reuse needles, syringes, vials of efalizumab, or syringes of sterile water. You can throw away used alcohol pads, needle caps, and vials in the trash. Throw away used needles and syringes in a puncture-resistant container out of the reach of children. Talk to your doctor or pharmacist about what to do with the puncture-resistant container when it is full.
Never mix efalizumab powder with any liquid other than the sterile water provided. Never add any other medications to the syringe you will use to inject efalizumab.
To prepare and inject efalizumab, follow these steps:
- Take one or two blister trays of efalizumab and supplies out of the refrigerator and place the tray(s) on a clean, well-lit, flat work surface. You will need one tray if your doctor has told you to inject 1.25 mL or less each week or two trays if your doctor has told you to inject more than 1.25 mL each week. You will also need to prepare sterile gauze and an adhesive bandage.
- Wash your hands well with soap and warm water.
- Open the blister tray(s) and place the contents on the work surface. Each tray should contain one vial of efalizumab, one prefilled syringe of sterile water, two alcohol pads, and two needles. The vial(s) of efalizumab and syringe(s) of sterile water should be marked with expiration dates that have not passed. Call your pharmacist if your tray(s) do not contain all of these supplies or if your medication or water has expired.
- Wait to allow the medication and water to warm to room temperatureSteps 5-14 tell how to mix efalizumab with sterile water. If your dose is more than 1.25 mL, you will need to follow these directions twice to prepare two separate vials of efalizumab.
- Remove the plastic cap from the vial of efalizumab and wipe the rubber stopper with an alcohol pad. When you handle the vial, be careful not to touch the rubber stopper with your fingers.
- Remove one of the needles from its package, but do not remove the cap.
- Remove the cap from the tip of the prefilled syringe, and place the capped needle onto the syringe tip. Twist the needle cap to secure it into place.
- Remove the cap from the needle but be careful not to touch the needle with your fingers.
- Place the vial of efalizumab upright on a firm surface and slowly push the needle through the rubber stopper.
- Aim the tip of the needle toward the wall of the vial and slowly push down on the plunger to inject all of the sterile water into the vial. The powder in the vial may foam when you inject the water.
- Leave the needle and syringe in the vial stopper. Pick up the vial and swirl it gently to mix the medication. Do not shake the vial.
- Wait 5 minutes to allow the medication to dissolve.
- Look at the vial to be sure it contains a clear or pale yellow liquid. Call your pharmacist and do not use the liquid if it is cloudy, contains particles, or is a different color.Steps 14-29 tell how to fill the syringe with the correct amount of medication and inject the medication. If your dose is more than 1.25 mL, you will need to follow these steps twice to fill and inject two syringes that each contain half of your dose.
- Pick up the vial and turn it upside down without removing the needle. The entire tip of the needle should be covered by the liquid in the vial.
- Pull back the plunger to fill the syringe with the amount of medication your doctor told you to use. (If your dose is more than 1.25 mL, you will fill the syringe with half the amount of medication your doctor told you to use and then prepare a second syringe containing the other half of your dose.) Line up the plunger with the right number on the side of the syringe to fill the syringe with the right amount of medication.
- Remove the needle and syringe from the vial. Place the needle cap on a flat surface and slide the needle into the cap. Push the cap all the way down over the needle.
- Hold the syringe upright and tap it to push any air bubbles to the top. Gently push in the plunger to push the air bubbles out.
- Check that the syringe contains the right amount of medication. If the amount of liquid in the syringe goes past the line that matches your dose, push the plunger up slowly to release the extra medication.
- Twist the capped needle off of the syringe and throw it away in a puncture-resistant container.
- Hold the plastic cover of the second needle and remove the needle from the package. Be careful not to touch the uncovered end of the needle.
- Place the capped needle on the syringe tip and twist it in place. Put the syringe and needle on a flat surface.
- Wash your hands and the skin in the area where you plan to inject the medication with soap and warm water.
- Let the skin in the area where you will inject efalizumab air dry, then clean it with an alcohol pad or alcohol-soaked cotton ball using a circular motion. Allow the skin to air dry again and do not touch it with your fingers until after you are finished injecting your medication.
- Pick up the syringe and remove the needle cap by twisting and pulling it. Be careful not to touch the needle to your fingers or any surface.
- Hold the syringe firmly between your thumb and fingers with one hand and use your other hand to pinch a fold of skin in the area where you will inject your medication.
- Push the needle straight into your skin at a 90-degree angle.
- Let go of the pinched fold of skin and use that hand to slowly push down on the plunger until it stops.
- Remove the needle from your skin and throw it away in a puncture-resistant container. Do not recap the needle.
- Use a dry sterile gauze pad to press down on the spot where you injected efalizumab. Do not use an alcohol wipe. You may cover the spot with a small bandage if needed.
Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before using efalizumab,
- tell your doctor and pharmacist if you are allergic to efalizumab or any other medications.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: other medications for psoriasis; oral steroids such as dexamethasone (Decadron, Dexone), methylprednisolone (Medrol), and prednisone (Deltasone); and medications that suppress the immune system such as azathioprine (Imuran), cancer chemotherapy medications, cyclosporine (Neoral, Sandimmune), methotrexate (Rheumatrex), sirolimus (Rapamune), and tacrolimus (Prograf). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you or any of your close relatives have or have ever had cancer or if you have or have ever had any disease that affects your immune system such as human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), or severe combined immunodeficiency syndrome (SCID), or if you have liver or kidney disease. Also tell your doctor if you have any type of infection, including infections that come and go (such as cold sores) and chronic infections that never go away, or if you frequently get any type of infection (such as urinary tract or bladder infections).
- tell your doctor if your psoriasis is being treated with phototherapy (a treatment for psoriasis that involves exposing the skin to ultraviolet light).
- tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while using efalizumab or within 6 weeks after you stop using efalizumab, call your doctor.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are using efalizumab.
- do not have any vaccinations (shots to prevent diseases) without talking to your doctor.
- you should know that efalizumab may decrease your ability to fight infection and increase the risk that you will develop a serious infection. Stay away from people who are sick and wash your hands often while you are using this medication.
- you should know that your psoriasis may worsen or you may develop a new type of psoriasis during or after your treatment with efalizumab. Call your doctor if you notice a new or worsening rash during or after your treatment.
- tell your doctor if you gain or lose weight while you are using efalizumab. Your doctor may have to change the dose of your medication if your weight changes. Do not change the dose of your medication without talking to your doctor.
What special dietary instructions should I follow?
Unless your doctor tells you otherwise, continue your normal diet.
What should I do if I forget a dose?
Call your doctor to find out when you should inject your next dose and what schedule you should follow after that. Never inject a double dose to make up for a missed one.
What side effects can this medication cause?
Efalizumab may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- headache, fever, chills, upset stomach, vomiting, and muscle pain within 48 hours of injecting the first two doses.
- back pain
- acne
Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:
- sore throat, fever, chills, cough, or other signs of infection
- flu-like symptoms
- easy bruising or bleeding
- bleeding gums
- tiny red spots under surface of skin
- weakness
- lightheadedness
- dark or red urine
- yellowing of the skin or eyes
- red, stiff, swollen, or painful joints
- hives
- itching
- difficulty breathing or swallowing
- wheezing
- swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
- hoarseness
- rash or blisters
- unusual skin changes or sores on the skin
- new lumps or masses anywhere in your body
Efalizumab may increase the risk that you will develop cancer. Talk to your doctor about the risks of using this medication.
Efalizumab may cause other side effects. Call your doctor if you have any unusual problems while using this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online [at http://www.fda.gov/MedWatch/index.html] or by phone [1-800-332-1088].
What storage conditions are needed for this medicine?
Keep this medication in the carton it came in, tightly closed, away from light, and out of reach of children. Store unopened blister trays of efalizumab in the refrigerator, but do not freeze them. You may store mixtures of efalizumab and sterile water for up to 8 hours at room temperature. Throw away mixtures of efalizumab and sterile water after 8 hours have passed and throw away any medication that is outdated or no longer needed. Talk to your pharmacist about the proper disposal of your medication.
In case of emergency/overdose
In case of overdose, call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911.
Symptoms of overdose may include:
- severe vomiting
What other information should I know?
Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to efalizumab.
Before having any laboratory tests, tell your doctor and the laboratory personnel that you are using efalizumab.
Do not let anyone else use your medication. Ask your pharmacist any questions you have about refilling your prescription.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
Brand name(s):
|